The total return over the past 12 months is -47.78% vs. +16.94% for the S&P 500. So far it's up -59.43% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (47.78%) | (1.97%) | (30.36%) | (43.20%) | (30.20%) | (24.80%) |
| Total Return CAGR | (47.78%) | (1.97%) | (30.36%) | (43.20%) | (30.20%) | (24.80%) |
| Revenue CAGR | (6.96%) | +7.23% | +5.15% | +3.50% | +1.46% | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Cardiff Oncology, Inc. (CRDF)
| Year | Start price | End price | CRDF Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $2.81 | $1.14 | (59.43%) | +14.51% | (73.94%) |
| 2025 | $4.34 | $2.81 | (35.25%) | +17.72% | (52.97%) |
| 2024 | $1.48 | $4.34 | +193.24% | +24.89% | +168.35% |
| 2023 | $1.40 | $1.48 | +5.71% | +26.19% | (20.48%) |
| 2022 | $6.01 | $1.40 | (76.71%) | (18.17%) | (58.54%) |
| 2021 | $17.99 | $6.01 | (66.59%) | +28.74% | (95.33%) |
| 2020 | $1.24 | $17.99 | +1350.81% | +18.37% | +1332.44% |
| 2019 | $3.18 | $1.24 | (61.01%) | +31.22% | (92.23%) |
| 2018 | $22.32 | $3.18 | (85.75%) | (4.56%) | (81.19%) |
| 2017 | $151.20 | $22.32 | (85.24%) | +21.70% | (106.94%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
